TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33258114
Drug: lanadelumab 300
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanadelumab 300 mg q2wks
Study: 32167001
Drug: D-alanine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-alanine (60 mg/kg)
Study: 35461158
Drug: Tofacitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (5 mg)
Study: 35461158
Drug: Xeljanz® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xeljanz® (5 mg)
Study: 32929234
Drug: ACC inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC inhibitor (pharmacologic inhibition of acetyl‐CoA carboxylase)
Study: 33070170
Drug: Horticultural Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural Therapy (HT) intervention over 6 months
Study: 33445959
Drug: Interpersonal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal and Social Rhythm Therapy (IPSRT)
Study: 33588758
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg once a day)
Study: 34872511
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) treatment alone
Study: 33038079
Drug: Comarum palustre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comarum palustre L. tablets 500 mg twice daily for 28 days
Study: 33534226
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics only
Study: 32887570
Drug: Sit-to-stand (STS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sit-to-stand (STS) exercises combined with Oral Nutritional Supplements (ONS) intake
Study: 36145090
Drug: Spirulina maxima
Normalized name: SPIRULINA MAXIMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina maxima 70% ethanol extract (SM70EE) 1 g/day
Study: 33097279
Drug: Vaccinated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated with live LaSota ND vaccine (CV)
Study: 33097279
Drug: Administered ND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered ND vaccine and 0.25 mg/kg body weight (BW) LPS (L‐LPS)
Study: 33097279
Drug: Administered ND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered ND vaccine and 0.5 mg/kg BW LPS (H‐LPS)
Study: 33394904
Drug: Low-frequency rTMS
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency rTMS with intensive speech therapy (ST)
Study: 33394904
Drug: 2 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 times a day low-frequency rTMS with intensive speech therapy (ST)
Study: 33394904
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intensive speech therapy only)
Study: 34618409
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection (ICI) of 100 units of BoNT‐A in 2 ml of saline
Study: 34618409
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of saline (control)
Study: 33044793
Drug: Lenvatinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (12 mg orally once daily for patients with a baseline body weight ≥60 kg and 8 mg orally once daily for patients with a baseline body weight <60 kg)
Study: 34530868
Drug: mHealth, CPN‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth, CPN‐administered decision support intervention
Study: 32447767
Drug: Jessner's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jessner's solution (JS)
Study: 35436290
Drug: T13‐Jeevamrut 16.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: T13‐Jeevamrut 16.08 L plant‐1 + Vermicompost 24.79 kg plant‐1
Study: 34376536
Drug: Early high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-dose glucocorticoids (GCC) use (≥60mg prednisone equivalent qd) after irAE onset
Study: 34376536
Drug: Early high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-dose GCC use
Study: 34376536
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (irAE without early high-dose GCC use)
Study: 32058596
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of octanoic acid‐rich MCT (OAR)
Study: 32058596
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of decanoic acid‐rich MCT (DAR)
Study: 32058596
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of MCT (OAR or DAR)
Study: 32058596
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of MCT (control)
Study: 35395951
Drug: felzartamab (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: felzartamab (16 mg/kg per infusion)
Study: 36463655
Drug: VR-based physical
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR-based physical activity program (24 sessions, 40 min each, twice a week)
Study: 33226501
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment plus daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10, ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02, ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus)
Study: 33226501
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days)
Study: 35276963
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (4000 IU daily for 12 weeks)
Study: 35460163
Drug: App-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based treatment for urinary incontinence
Study: 33509974
Drug: Oral ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ingestion of MSG
Study: 33509974
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application (swishing) of MSG
Study: 32366156
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of empagliflozin 5 mg/linagliptin 2.5 mg/metformin XR 1000 mg
Study: 32366156
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of empagliflozin 25 mg/linagliptin 5 mg/metformin XR 1000 mg
Study: 32366156
Drug: Free tablet
Normalized name: Fosfree Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free tablet combinations of empagliflozin/linagliptin/metformin XR
Study: 34864785
Drug: Sustained WHO
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained WHO risk drinking reductions of 2 or more levels throughout treatment
Study: 32997744
Drug: Immediate isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate isoniazid preventive therapy (IPT) during pregnancy
Study: 33820572
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (600 μg RAE/d)
Study: 33820572
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (10 μg/d)
Study: 33820572
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vitamin A (600 μg RAE/d) and Vitamin D (10 μg/d)
Study: 33820572
Drug: Standard anti-tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-tuberculosis treatment alone (Control group)
Study: 34233913
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of allogenic cardiosphere-derived cells (CDCs)
Study: 34371963
Drug: Hydrolyzed chicken
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrolyzed chicken collagen type II (HCII) supplement
Study: 35753964
Drug: Tailored over-the-counter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored over-the-counter medication safety intervention
Study: 34945739
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline bolus and midazolam infusion [0.05 mg/kg loading, 20 µg/kg/h thereafter])
Study: 34945739
Drug: DMED (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMED (saline bolus and dexmedetomidine infusion [1 µg/kg loading, 0.4 µg/kg/h thereafter])
Study: 34945739
Drug: DEXA (dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEXA (dexamethasone [10 mg] bolus and midazolam infusion)
Study: 34945739
Drug: DMED‐DEXA (dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMED‐DEXA (dexmedetomidine infusion and dexamethasone bolus)
Study: 34964676
Drug: Electrophysiology-based software-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiology-based software-guided cochlear implant fitting method (5-electrode method)
Study: 34964676
Drug: Electrophysiology-based software-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiology-based software-guided cochlear implant fitting method (all 22 electrodes)
Study: 32517693
Drug: erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: erenumab 70 mg and 140 mg
Study: 39575611
Drug: Morphine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine therapy
Study: 33252480
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg daily (10 mg if co-administered with ritonavir/cobicistat)
Study: 35461831
Drug: Aflibercept or
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept or bevacizumab treatment
Study: 33812296
Drug: Family participatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family participatory dignity therapy (2-3 interviews lasting 45-60 minutes each)
Study: 33812296
Drug: Family participatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family participatory dignity therapy
Study: 34281600
Drug: Suxiao Jiuxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxiao Jiuxin Pill (SJP)
Study: 33238677
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (0.5 ml/kg)
Study: 33238677
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (0.8 ml/kg, flow rate 5 ml/s)
Study: 33238677
Drug: Flow rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow rates of contrast agents
Study: 33238677
Drug: Amount of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amount of contrast agent
Study: 33238677
Drug: Effective dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective dose (ED)
Study: 34839364
Drug: KET 0.5
Normalized name: Isoket 0.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: KET 0.5 (0.5 mg/kg)
Study: 34839364
Drug: MID (midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: MID (midazolam 0.03 mg/kg)
Study: 34930986
Drug: Dapagliflozin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin combined with Metformin
Study: 34657640
Drug: L-arabinose (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arabinose (7.5 g) co-ingested with sucrose (50 g)
Study: 34657640
Drug: Control (sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sucrose 50 g without L-arabinose)
Study: 35240074
Drug: Avatrombopag 60
Normalized name: avatrombopag 60 MG Daily Dose, 20 MG Oral Tablet 15 Count Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag 60 mg once daily for 5 days before and after chemotherapy
Study: 34186380
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea mouthwash (100 ml for 60 seconds after brushing)
Study: 34186380
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water mouthwash (100 ml for 60 seconds after brushing)
Study: 36222372
Drug: Danofloxacin 5
Normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danofloxacin 5 mg/kg body weight, administered orally (PO)
Study: 36222372
Drug: Danofloxacin 5
Normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danofloxacin 5 mg/kg body weight, administered intravenously (IV)
Study: 32791711
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (waiting treatment)
Study: 32791711
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (rMS, rTMS, No treatment)
Study: 34237132
Drug: Anterior quadratus
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior quadratus lumborum block with multimodal analgesia (30 ml bupivacaine 0.5% with 2 mg preservative-free dexamethasone)
Study: 39303788
Drug: High-dose quadrivalent
Normalized name: Fluzone High-Dose Quadrivalent PF 2020-2021
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose quadrivalent influenza vaccine (QIV-HD)
Study: 33230964
Drug: Small Changes
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small Changes (daily small changes in intake and activity)
Study: 33120774
Drug: Triple injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple injection (TI group, n=34)
Study: 33120774
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection (SI group, n=34)
Study: 36075249
Drug: ABX464 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 100 mg
Study: 36075249
Drug: ABX464 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 25 mg
Study: 33405297
Drug: Increasing insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing insulin dose (100% to 160% ICR)
Study: 35982198
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine bolus of 1.5 mg/kg over 5 min followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively
Study: 33186492
Drug: Polypill (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (40 mg simvastatin, 100 mg atenolol, 25 mg hydrochlorothiazide, 10 mg ramipril)
Study: 33186492
Drug: Polypill plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill plus Aspirin
Study: 33106446
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg, 20 min before surgery)
Study: 33106446
Drug: Psychological preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological preparation (booklet and explanation by anaesthesia resident)
Study: 36424542
Drug: Azithromycin 1000
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1000 mg PO once
Study: 36424542
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg PO once, followed by Azithromycin 250 mg PO daily for four days
Study: 33693468
Drug: Provitamin A
Normalized name: Provitamin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provitamin A carotenoid-biofortified maize (∼315 µg RE/d to mothers and ∼55 µg RE/d to infants)
Study: 33693468
Drug: Retinyl palmitate-fortified
Normalized name: RETINYL PALMITATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl palmitate-fortified maize (∼315 µg RE/d to mothers and ∼55 µg RE/d to infants)
Study: 33693468
Drug: Conventional maize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional maize (0 µg RE/d)
Study: 34105265
Drug: Aripiprazole orally
Normalized name: Aripiprazole Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole orally disintegrating tablets (10 mg) in fasting state
Study: 34105265
Drug: Aripiprazole orally
Normalized name: Aripiprazole Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole orally disintegrating tablets (10 mg) in fed state
Study: 34105265
Drug: Test and
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test and reference formulations (both fasting and fed conditions)
Study: 34105265
Drug: Test and
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test and reference formulations
Study: 33075170
Drug: Sublingual wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual wafer (25 mg CBD)
Study: 33075170
Drug: Sublingual wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual wafer (50 mg CBD)
Study: 33075170
Drug: Oil solution
Normalized name: Today's Health Mineral Oil Solution
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil solution (50 mg CBD)
Study: 33075170
Drug: Nabiximols oromucosal
Normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols oromucosal spray (20 mg CBD, 21.6 mg THC)
Study: 33075170
Drug: Sublingual wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual wafer (50 mg CBD, multiple doses)
Study: 33075170
Drug: Sublingual wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual wafer and oil solution
Study: 33030035
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection (control group)
Study: 32407460
Drug: Low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose colchicine (0.5 mg once daily)
Study: 33884972
Drug: Sevoflurane-propofol combination
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane-propofol combination
Study: 35660971
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily (EXP2–3A)
Study: 35660971
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily (EXP3B–5)
Study: 38434770
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily
Study: 33068751
Drug: Active TNS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TNS treatment for 4 weeks
Study: 33068751
Drug: Sham TNS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham TNS treatment for 4 weeks (control)
Study: 34903257
Drug: Home-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based intervention combining psychological treatment for depression and a parenting programme (10 sessions: 4 antenatal and 6 postnatal sessions, plus a booster session at 16 months)
Study: 35433421
Drug: Pembrolizumab combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab combined with neoadjuvant chemotherapy (neoCT)
Study: 33142521
Drug: Phytosterols (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterols (25 mg/kg)
Study: 33142521
Drug: Antibiotics (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (200 mg/kg oxytetracycline calcium and 250 mg/kg nosiheptide)
Study: 35596529
Drug: Intravenous perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous perampanel (12 mg) administered via 30- or 60-minute infusion
Study: 35596529
Drug: Intravenous perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous perampanel (12 mg)
Study: 35596529
Drug: Intravenous perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous perampanel
Study: 33389521
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg dexamethasone phosphate (DEX-P) administered orally (PO)
Study: 33389521
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg betamethasone phosphate (BET-P) administered orally (PO)
Study: 33389521
Drug: 1:1 mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 mixture of betamethasone phosphate and acetate (BET-PA) administered intramuscularly (IM)
Study: 33181081
Drug: Febuxostat (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (80 mg/day, increasing to 120 mg/day if necessary)
Study: 33181081
Drug: Allopurinol (optimised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (optimised dose)
Study: 34119741
Drug: JianpiQinghua (JQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JianpiQinghua (JQ) granules (34.8 g) plus omeprazole (10 mg)
Study: 32133684
Drug: Digital Patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Patient Journey (DPJ) solution
Study: 33445218
Drug: Endoscopic cyanoacrylate
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic cyanoacrylate injection
Study: 33032180
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral nutritional supplements (ONS) from the beginning of CCRT
Study: 34071293
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (10,000 IU daily for 14 days)
Study: 34980026
Drug: PHI-101 (Chk2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHI-101 (Chk2 inhibitor)
Study: 34209617
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day of Golden Root Extract (GRE; Rhodiola rosea)
Study: 35083729
Drug: Probiotic drops
Normalized name: UpSpring Baby Probiotic Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic drops containing Limosilactobacillus reuteri (DSM 17938 and ATCC PTA 5289) given as 5 daily drops at bedtime for 12 months.
Study: 34658247
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rivaroxaban plus antiplatelet drug
Study: 32556409
Drug: Biological graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological graft for EAS repair